Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Ashley Teusink‐Cross"'
Autor:
Andrea Edwards, Ashley Teusink‐Cross, Lisa J. Martin, Cynthia A. Prows, Parinda A. Mehta, Laura B. Ramsey
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 3, Pp 610-618 (2022)
Abstract Chemotherapy‐induced nausea and vomiting (CINV) is commonly experienced by patients receiving antineoplastic agents prior to hemopoietic stem cell transplant (HSCT). Ondansetron, a 5‐HT3 antagonist metabolized by CYP2D6, is an antiemetic
Externí odkaz:
https://doaj.org/article/049767258135467290e37ec23abfcaba
Graft rejection markers in children undergoing hematopoietic cell transplant for bone marrow failure
Autor:
Adam Lane, Kasiani C. Myers, Stella M. Davies, Anthony Sabulski, Sonata Jodele, Alexandra Duell, Jack J. Bleesing, Ashley Teusink-Cross
Publikováno v:
Blood Advances
Key Points CXCL9, BAFF, and sC5b-9 are potential biomarkers and therapeutic targets for graft rejection after transplant.Fever monitoring is a widely available and informative predictor of graft rejection after transplant.
Visual Abstract
G
Visual Abstract
G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20fb1af4a730fe4640b42f74fc3b48d3
https://doi.org/10.1182/bloodadvances.2021005231
https://doi.org/10.1182/bloodadvances.2021005231
Autor:
Thomas J. Galletta, Min Dong, Alexander A. Vinks, Samuel C.C. Chiang, Ashley Teusink-Cross, Rebecca A. Marsh, Stella M. Davies, Parinda A. Mehta, Pooja Khandelwal
Publikováno v:
Transplantation and Cellular Therapy. 29:S271-S272
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05c07c523d63daa4256295451ff1c9a3
https://doi.org/10.1016/s2666-6367(23)00425-6
https://doi.org/10.1016/s2666-6367(23)00425-6
Autor:
Pooja Khandelwal, Lucille Langenberg, Nathan Luebbering, Cynthia B Taggart, Kelly E Lake, Kylie Werling, Abigail Butcher, Hannah Choe, Sumithira Vasu, Ashley Teusink-Cross, Gregory Wallace, Adam Lane, Stella M. Davies
Publikováno v:
Transplantation and Cellular Therapy. 29:S93-S94
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::948bb542000bacd241244888a28a2364
https://doi.org/10.1016/s2666-6367(23)00186-0
https://doi.org/10.1016/s2666-6367(23)00186-0
Autor:
Stella M. Davies, Emma M.R. Perentesis, Ashley Teusink-Cross, Gregory Wallace, Kasiani C. Myers, Sonata Jodele, Adam Lane, Kristi Smiley, Pooja Khandelwal
Publikováno v:
Bone Marrow Transplant
Skin graft versus host disease (GVHD) can affect quality of life in hematopoietic stem cell transplant recipients. Therapeutic options for steroid-refractory GVHD are limited. We report the first prospective pilot study evaluating the topical vitamin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5053f123de3ab46d92fd622a837a0912
https://doi.org/10.1038/s41409-020-01189-3
https://doi.org/10.1038/s41409-020-01189-3
Autor:
Sonata Jodele, Christopher E. Dandoy, Anthony Sabulski, Jane Koo, Adam Lane, Kasiani C. Myers, Gregory Wallace, Ranjit S. Chima, Ashley Teusink-Cross, Russel Hirsch, Thomas D. Ryan, Stefanie Benoit, Stella M. Davies
Publikováno v:
Transplant Cell Ther
Transplantation-associated thrombotic microangiopathy (TA-TMA) can range from a self-limiting condition to a lethal transplantation complication. It is important to identify TA-TMA patients at risk for severe multiorgan endothelial injury to implemen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3b0f0f5fe99ad83d2eaa13a65081d2b
https://europepmc.org/articles/PMC9351710/
https://europepmc.org/articles/PMC9351710/
Autor:
Lisa Neumeier, Kelly McIntosh, Adam S. Nelson, Adam Lane, Min Dong, Tsuyoshi Fukuda, Danielle E. Arnold, Parinda A. Mehta, Federica Achini, Sharat Chandra, Arjan C. Lankester, Alexander A. Vinks, Ashley Teusink-Cross, Chie Emoto, Rebecca A. Marsh, Michael B. Jordan, Kasiani C. Myers, Stella M. Davies
Publikováno v:
Bone Marrow Transplantation. SPRINGERNATURE
Bone Marrow Transplantation
Bone Marrow Transplantation
Alemtuzumab is used as part of reduced-intensity and reduced-toxicity transplant conditioning regimens for nonmalignant diseases. Prior studies identified an ideal target concentration range of 0.15-0.6 mcg/mL at day 0. However, only 24% of patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5077b1484933ad0642391922ff3fd69
https://doi.org/10.1038/s41409-021-01460-1
https://doi.org/10.1038/s41409-021-01460-1
Autor:
J.J. Bleesing, Adam Lane, Michael B. Jordan, Pooja Khandelwal, Mary Christa Krupski, Tsuyoshi Fukuda, Adam S. Nelson, Parinda A. Mehta, Ashley Teusink-Cross, Angela D. M. Kashuba, Kasiani C. Myers, Javier El-Bietar, Sharat Chandra, Michael Grimley, Rebecca A. Marsh, Stella M. Davies
Publikováno v:
Bone Marrow Transplantation. 55:1552-1559
We report results of a phase II study of maraviroc to prevent acute graft versus host disease (GVHD) in children undergoing allogeneic hematopoietic stem cell transplant (HSCT). Oral maraviroc was added to standard GVHD prophylaxis of a calcineurin i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a73e8ade464104d951daf5f3e234013
https://doi.org/10.1038/s41409-020-0888-3
https://doi.org/10.1038/s41409-020-0888-3
Autor:
Kana Mizuno, Christopher E. Dandoy, Ashley Teusink-Cross, Stella M. Davies, Alexander A. Vinks, Sonata Jodele
Publikováno v:
Blood advances. 6(5)
Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal posttransplant complication of hematopoietic stem cell transplantation. We recently reported that survival for TA-TMA has been improved by early intervention with eculizumab, a comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::214dbd55db59c2fe3c31ed505cacbeb0
https://pubmed.ncbi.nlm.nih.gov/35008105
https://pubmed.ncbi.nlm.nih.gov/35008105
Autor:
Julia C. Gardner, Joshua D. Courter, Christopher E. Dandoy, Stella M. Davies, Ashley Teusink-Cross
Publikováno v:
Transplantation and cellular therapy. 28(3)
Levofloxacin has been widely used for bacteremia prophylaxis in the pre-engraftment setting for patients undergoing hematopoietic stem cell transplantation (HSCT), but data supporting this practice are inconsistent. In addition to concern for lack of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1ca3a8acc6ff10bc759dc0f42909b16
https://pubmed.ncbi.nlm.nih.gov/34875405
https://pubmed.ncbi.nlm.nih.gov/34875405